[SunilNagpal]

AMGEN Inc. one of the world's leading bio-pharmaceutical company, based in United States (Headquartered in California) is well known for the R&D and Manufacturing of human therapeutics. Here are some of the latest developments that took place in AMGEN, along with the update on recent job openings:

• Amgen Award for Science Teaching Excellence (AASTE) Winners Declared
  

AASTE by Amgen is a unique initiative of Amgen in recognizing talented teachers rendering their services in public and private schools of United States, Puerto Rico and Canada. The award is given every year to a selected few excellent teachers.
Here's the list of Winners 2013 (Announced on June 19, 2013):
1. Laura Todis (Sierra High School, Fillmore, CA)
2. Mary Murphy (The Urban School of San Francisco, San Francisco, CA)
3. Mark Paricio (Smoky Hill High School, Aurora, CO)
4. Susan Buehner (Brandeis Elementary School, Louisville, KY)
5. Rebekah Ravgiala (Tyngsborough High School, Tyngsborough, MA)
6. Luz Burgos (Colegio Radians, Cayey, Puerto Rico)
7. David Upegui (Central Falls High School, Central Falls, RI)
8. Amanda Rainwater (Bothell High School, Bothell, WA)
9. Glyn Davies (Henry Anderson Elementary School, Richmond, B.C., Canada)

Click here for Details

• Amgen's XGEVA (denosumab), drug for the Treatment Of Giant Cell Tumor Of Bone (GCTB) Approved by FDA
  

XGEVA, the RANKL (RANK Ligand, a protein that signals the removal of bone) inhibitor, is the first ever FDA approved drug against the rare disease GCTB. Earlier in 2010, XGEVA was approved by FDA as a drug for the prevention of skeletal-related events (SREs) in patients with bone metastases from solid tumors.

GCTB is a highly destructive tumorous disease that leads to deformation and fracturing of the bones. Individuals in the age group of 20-40 are more vulnerable to this rare disease. In such a scenario, XGEVA has emerged as a ray of hope, being the only treatment available now.

Click here for Details

• AMGEN Inc Enters Into Strategic Alliance With Astellas Pharma Inc
  

AMGEN and Astellas (a leading Tokyo-based global pharmaceutical company) announced a strategic alliance to improve the medical therapeutic conditions in Japan, and improve the healthcare reform systems for Japanese Patients, on May 29, 2013. As a part of the alliance, the two companies will also establish a Joint Venture (JV) company in Tokyo to increase the pace of reformatory actions and act at grass root level.

Click here for Details

• Positions Open at Research & Development Wing of AMGEN, California, US
  

Note down the job code from the list below and apply here

The Thread Will Be Updated With New Information As And When Available.

Readers May Feel Free To Add The Updates!

Thanks for Reading!